Last update 17 Apr 2025

PF-06688992

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
GD3 ADC, PF 06688992
Target
GD3 x Tubulin
Action
inhibitors
Mechanism
GD3 inhibitors(Ganglioside GD3 inhibitors), Tubulin inhibitors
Therapeutic Areas
NeoplasmsImmune System DiseasesCardiovascular Diseases+ [1]
Active Indication
Multiple Myeloma
Inactive Indication
Unresectable Melanoma
Originator Organization
Pfizer Inc.Pfizer Inc.
Active Organization
Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer CenterPfizer Inc.Pfizer Inc.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC11H22N4O4
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N
CAS Registry159858-33-0
View All Structures (2)
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with PF-06688992
NCT03159117
/ CompletedPhase 1IIT
A Phase I Open-Label Dose Escalation of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568)
100 Clinical Results associated with PF-06688992
Login to view more data
100 Translational Medicine associated with PF-06688992
Login to view more data
100 Patents (Medical) associated with PF-06688992
Login to view more data
100 Deals associated with PF-06688992
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Unresectable MelanomaPhase 1
United States
Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center
16 May 2017
Unresectable MelanomaPhase 1
United States
Pfizer Inc.Pfizer Inc.
16 May 2017
Multiple MyelomaPhase 1-
Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center
-
Multiple MyelomaPhase 1-
Pfizer Inc.Pfizer Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free